{
    "nct_id": "NCT03956680",
    "official_title": "A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers",
    "inclusion_criteria": "* Histologically or cytologically confirmed advanced unresectable/metastatic malignancy of the squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), and urothelial carcinoma (UCC), that are refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant\n* Must have experienced radiographically documented progressive disease on or after the most recent therapy\n* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n* Women and men must agree to follow specific methods of contraception, if applicable, while participating in the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary central nervous system (CNS) malignancy\n* Other active malignancy requiring concurrent intervention\n* Uncontrolled or significant cardiovascular disease\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}